Literature DB >> 20373055

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.

Chuan-Yong Mu1, Jian-An Huang, Ying Chen, Cheng Chen, Xue-Guang Zhang.   

Abstract

The immunohistochemical analysis was used to evaluate the expression of PD-L1 in 109 non-small cell lung cancer (NSCLC) tissues and para-tumor tissues. Associations between expressed PD-L1 and tumor histological types, degree of differentiation, and lymph node metastasis were calculated, and overall survival was assessed. Meanwhile, immunohistochemistry and immunofluorescence double labeling technique were performed to detect the expressions of PD-L1, CD1α, and CD83 on TIDC of 20 lung cancer tissues, and the expression of PD-L1 in CD1α+DCs and CD83+DCs and their significances were also explored. We found that the expression rate of PD-L1 in NSCLC was associated with histological types and overall survival. Patients with either adenocarcinoma or survival time after surgery less than 3 years showed higher expression rate of PD-L1. Furthermore, Cox model analysis indicated that PD-L1 might be regarded as a poor prognostic factor. PD-L1 could be also detected in CD1α+ immature DC in NSCLC, indicating that as a class of key anti-tumor immunocyte in tumor microenvironment, DC expressing PD-L1 itself might play an important role in keeping its immature status and contributing to tumor cells immune escape and disease progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373055     DOI: 10.1007/s12032-010-9515-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.

Authors:  Xiulong Xu; Geetha Rao; Michael J Gaffud; Helen G Ding; Guitta Maki; Hans-G Klingemann; Veronika Groh; Thomas Spies; Sophie Caillat-Zucman; Paolo Gattuso; Janet Plate; Richard A Prinz
Journal:  J Clin Endocrinol Metab       Date:  2006-04-18       Impact factor: 5.958

2.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

Authors:  L J Zhou; T F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 3.  Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity.

Authors:  R Kim; M Emi; K Tanabe
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

4.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

Review 5.  Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.

Authors:  Matthias Schott
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

6.  Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage.

Authors:  Ivan Perrot; Dominique Blanchard; Nathalie Freymond; Sylvie Isaac; Benoît Guibert; Yves Pachéco; Serge Lebecque
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

7.  Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer.

Authors:  L Kaklamanis; A Townsend; I A Doussis-Anagnostopoulou; N Mortensen; A L Harris; K C Gatter
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Authors:  Christian Blank; Juergen Kuball; Simon Voelkl; Heinz Wiendl; Bernd Becker; Bernhard Walter; Otto Majdic; Thomas F Gajewski; Mathias Theobald; Reinhard Andreesen; Andreas Mackensen
Journal:  Int J Cancer       Date:  2006-07-15       Impact factor: 7.396

Review 9.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

10.  Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Authors:  Mary E Keir; Spencer C Liang; Indira Guleria; Yvette E Latchman; Andi Qipo; Lee A Albacker; Maria Koulmanda; Gordon J Freeman; Mohamed H Sayegh; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

View more
  246 in total

Review 1.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation.

Authors:  Hiroaki Inaba; Hideyuki Sugita; Masae Kuboniwa; Soichi Iwai; Masakazu Hamada; Takeshi Noda; Ichijiro Morisaki; Richard J Lamont; Atsuo Amano
Journal:  Cell Microbiol       Date:  2013-09-19       Impact factor: 3.715

3.  PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Ze-Jun Zhou; Ping Zhan; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 4.  Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Authors:  A Mitsuhashi; Y Okuma
Journal:  Clin Transl Oncol       Date:  2018-01-08       Impact factor: 3.405

5.  BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.

Authors:  J Wang; Y Jia; S Zhao; X Zhang; X Wang; X Han; Y Wang; M Ma; J Shi; L Liu
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

6.  A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.

Authors:  Jian Zhang; Huizhong Li; Dazhi Gao; Baofu Zhang; Maojin Zheng; Mingyin Lun; Mengxue Wei; Rui Duan; Maomao Guo; Jiajun Hua; Qian Liu; Jin Bai; Hui Liu; Junnian Zheng; Hong Yao
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

7.  Programmed death ligand-1 expression in non-small cell lung cancer.

Authors:  Vamsidhar Velcheti; Kurt A Schalper; Daniel E Carvajal; Valsamo K Anagnostou; Konstantinos N Syrigos; Mario Sznol; Roy S Herbst; Scott N Gettinger; Lieping Chen; David L Rimm
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

8.  Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.

Authors:  Roberta Carosio; Vincenzo Fontana; Luca Mastracci; Paola Ferro; Federica Grillo; Barbara Banelli; Pier Aldo Canessa; Paolo Dessanti; Antonella Vigani; Anna Morabito; Ulrich Pfeffer; Alessandro Poggi; Silvio Roncella; Maria Pia Pistillo
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-20       Impact factor: 4.553

9.  Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.

Authors:  Cuiling Zhou; Gang Che; Xiaobin Zheng; Junlan Qiu; Zhinan Xie; Yunyan Cong; Xiaofeng Pei; Hongyu Zhang; Huanhuan Sun; Haiqing Ma
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-20       Impact factor: 4.553

Review 10.  Immune checkpoint inhibitors in NSCLC.

Authors:  Douglas B Johnson; Matthew J Rioth; Leora Horn
Journal:  Curr Treat Options Oncol       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.